Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 713,526 | 433,584 | 113,432 | 100,488 | 162,531 |
| Marketable Securities | 488,007 | 321,646 | 346,274 | 134,005 | 219,028 |
| Receivables | 23,093 | 32,844 | 12,740 | 5,172 | N/A |
| Inventories | 13,048 | 11,546 | 7,065 | 757 | N/A |
| TOTAL | $1,295,304 | $851,017 | $522,369 | $269,583 | $401,695 |
| Non-Current Assets | |||||
| PPE Net | 73,515 | 44,348 | 20,046 | 21,837 | 17,055 |
| Investments And Advances | 165,881 | 32,926 | 0 | 9,975 | 117,963 |
| Intangibles | 175,519 | 173,406 | 173,629 | 185,951 | 0 |
| Other Non-Current Assets | 49,336 | 33,799 | 3,514 | 3,407 | 3,913 |
| TOTAL | $464,251 | $284,479 | $197,189 | $221,170 | $138,931 |
| Total Assets | $1,759,555 | $1,135,496 | $719,558 | $490,753 | $540,626 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 12,923 | 12,871 | 12,275 | 8,886 | 5,364 |
| Accrued Expenses | 108,491 | 83,194 | 62,450 | 62,128 | 54,554 |
| Other current liabilities | 59,219 | N/A | N/A | N/A | N/A |
| TOTAL | $189,609 | $103,300 | $74,725 | $71,014 | $60,259 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 341 |
| Other Non-Current Liabilities | 382,265 | 345,126 | 4,759 | 5,119 | 6,393 |
| TOTAL | $415,571 | $378,432 | $35,925 | $36,285 | $6,393 |
| Total Liabilities | $605,180 | $481,732 | $110,650 | $107,299 | $66,652 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 66,949 | 57,889 | 51,279 | 49,606 | 41,727 |
| Common Shares | 67 | 58 | 51 | 44 | 41 |
| Retained earnings | -1,619,576 | -1,433,010 | -1,030,283 | -832,672 | -530,533 |
| Other shareholders' equity | 689 | -147 | -633 | -5,680 | 905 |
| TOTAL | $1,154,375 | $653,764 | $608,908 | $383,454 | $473,974 |
| Total Liabilities And Equity | $1,759,555 | $1,135,496 | $719,558 | $490,753 | $540,626 |